A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Tahseen Mozaffar, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UC Irvine
- Tahseen Mozaffar, MD
Clinical Professor, Neurology, School of Medicine. Authored (or co-authored) 155 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Asklepios Biopharmaceutical, Inc.
- ID
- NCT05230459
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 10 study participants
- Last Updated